Simply going from the FDA definition of BTD (does not state a specific number of patients), our TNBC trial protocol / design, I believe there is a good chance of BTD approval. For starters, I don't believe CYDY filed based on only two patients in attempt to challenge the FDA....or in other words I think they have had some discussion about what is acceptable criteria for BTD filing and approval.....I think the FDA knows leronlimab well enough by now to have some respect for it and its potential for many indications, but I don't know how the FDA will decide on this and I have not compared to previous BTD approvals to determine a baseline for a number of patients.....I intentionally have not done so because I don't think there are other drugs out there that would be an apples-to-apples comparison given the extensive proven safety record that is shown such amazing results for an extremely deadly condition which it has not been in testing for until very recently. I would guess most previous BTD approvals are for drugs designed for their indication, limited proven safety profile on a much smaller sample size than 840, and granted simply based on early P2 efficacy / results for a serious condition. Some of these may only temporarily help before resistance builds, toxicity, may only work on 20% of patients, etc. but there isn't a better options currently available.
Maybe I am biased or naive, but with the proven safety of leronlimab, surrogate endpoints of CTCs, reduced tumor sizes proven with MRI and CT scans, and many other conditions that have stabilized, TNBC (cancer in general) being such a deadly disease and all the data thus far aligns with progression free survival (PFS)......plus I think the bar is set pretty low for a safe and effective drug such as leronlimab. If this works in 100% of patients who screen positive for CCR5 on the tumor itself or on the macrophages surrounding the tumor, whether this be 4 patients, 7 patients, or 100 patients these results in cancer are very rare!
I know this has been discussed here before, but IMO if they get BTD approval, Accelerated Approval will also be granted. I don't have other examples to compare, but again I don't think there is a comparable situation to provide precedence to our situation.
But to me, isn't necessarily if/when we get BTD or TNBC/MBC cancer approved, but completing the BLA, getting combo HIV approved and continue showing impressive cancer results. If these happen, it will not matter if we received BTD or cancer is approved, it will be used extensively off-label for cancer/s that are proven or showing promise based on early trial and emergency patient results.
(10)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
Introduction to OneMedNet Corporation
Leading curating and managing of regulatory-grade Real World Data (RWD) is OneMedNet Corporation (Nasdaq: ONMD). By including its own artificial intelligence technology into its data curating procedures, the company has lately made a big advance. Along with simplifying the de-identification of patient data, this invention significantly cut running expenses. OneMedNet has improved its capacity to process enormous volumes of clinical data by using artificia... Continue Reading
Symbotic Expands Capabilities with Strategic Acquisition
Leader in A.I.-enabled robotics technology Symbolic Inc. (Nasdaq: SYM) has made a big advance by acquiring Veo Robotics' assets. This purchase seeks to improve Symbotic's capacity for field-based industrial automation innovation, especially in settings where humans and robots collaborate. By including Veo Robotics' FreeMove® 3D vision system, Symbolic will be able to guarantee worker safety while raising output. Bringing... Continue Reading
Norwegian Cruise Line Holdings' Support for Juneau Flood Recovery
Assistance of flood recovery in Juneau, Alaska, has come largely from Norwegian Cruise Line Holdings (NYSE: NCLH). Targeting financial aid for persons affected by the recent floods, the company gave $50,000 to the Juneau Community Foundation. The donation from NCLH concentrates on helping residents whose needs FEMA might not completely satisfy. Said to be the worst in Juneau's history, the floods started by the Mendenha... Continue Reading
Category: StocksTotal Views: 295 By : Lucas YoungUpdated: 08-09-2024
Diamond Creek High Alkaline Water by Accredited Solutions, Inc.
Under the Diamond Creek brand, Accredited Solutions, Inc. (OTC: ASII) markets strong alkaline water products. Source from natural springs, Diamond Creek High Alkaline Water boasts a pH of 9.5. One-gallon, one-liter, and half-liter bottles are among the ones it comes in. The water is meant to aid pH balance and hydration. Diamond Creek is positioned as a premium offering for consumers with health consciousness. Grocery and conveni... Continue Reading
Cherokee Federal Expands Presence in Washington, D.C.
Significantly expanding the Washington, D.C. region, Cherokee Federal has announced the opening of a new office in Tysons Corner. This action helps the company to better serve its federal customers since it fits its continuous growth plan. Strategically placed within Greensboro Park, the new office offers quick access to many government departments. Along with improving Cherokee Federal's geographical presence, this growth shows its wi... Continue Reading
Liberty Defense Completes HEXWAVE Installations at Key Airports
Major American and Canadian airports have seen Liberty Defense Holdings Ltd. (TSXV: SCAN) (OTCQB: LDDFF) (FRANKFURT: LD2A) successfully install its HEXWAVE system. These installations represent a major progress in improving security protocols at these sites. Renowned for its sophisticated threat detection features, the HEXWAVE system is now running at Rochester and Manchester Airports, guaranteeing adherence to new security requi... Continue Reading
Iteris Acquisition Overview
Entering into a definitive merger agreement with Italian digital innovation group Almaviva S.p.A., Iteris, Inc. (NASDAQ: ITI) has acquisition values of almost $335 million in equity; its shareholders are set to get $7.20 each in cash. At 68% above the closing share price of the company as of August 8, 2024, this marks a notable premium. The agreement captures Iteris's strong market leadership in smart mobility infrastructure management. Approved unanimously by ... Continue Reading
Curaleaf Expands Presence with New Pensacola Dispensary
With its 63rd site in the state and 149th across the country, Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF), has announced the opening of a new dispensary in Pensacola, Florida. This growth supports the company's dedication to provide cannabis products—especially in underprivileged areas—more widely throughout the state. Strategically placed in the historic Nine Mile Road retail area of the city, the Pensacola site g... Continue Reading
Vinanz Expands Bitcoin Mining in Iowa
A major change in Vinanz Limited's North American approach is the greatly increased Bitcoin mining activities it conducts in Iowa. First, in June the company set up 20 Bitmain Antminer S19J Pro+ 120 Terahash (TH) miners at Mining Store's St. Anthony site. After first deployment, Vinanz rapidly expanded its activities by ordering forty more miners in the same month. The company bought 20 more units after these miners were delivered and put in place... Continue Reading
Discovery of Spodumene by Usha Resources at White Willow Project
At its White Willow Lithium Pegmatite Project, Usha Resources (TSXV: USHA) (OTCQB: USHAF) (FSE: JO0) has effectively discovered spodumene. This finding marks a turning point in validation of the company's exploration thesis developed over the past 15 months. Originally based on high-grade Tantalite results, the project now comprises a spodumene-bearing pegmatite system with a strike length of almost 44 kilometers. The d... Continue Reading